Verapamil Hexal may be available in the countries listed below.
Verapamil hydrochloride (a derivative of Verapamil) is reported as an ingredient of Verapamil Hexal in the following countries:
International Drug Name Search
Fenindione may be available in the countries listed below.
Fenindione (DCIT) is also known as Phenindione (Rec.INN)
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Neuzym may be available in the countries listed below.
Lysozyme hydrochloride (a derivative of Lysozyme) is reported as an ingredient of Neuzym in the following countries:
International Drug Name Search
Niflucan may be available in the countries listed below.
Flunarizine dihydrochloride (a derivative of Flunarizine) is reported as an ingredient of Niflucan in the following countries:
International Drug Name Search
Unimazole may be available in the countries listed below.
Thiamazole is reported as an ingredient of Unimazole in the following countries:
International Drug Name Search
Nisutadil may be available in the countries listed below.
Nicardipine hydrochloride (a derivative of Nicardipine) is reported as an ingredient of Nisutadil in the following countries:
International Drug Name Search
Partusisten may be available in the countries listed below.
Fenoterol hydrobromide (a derivative of Fenoterol) is reported as an ingredient of Partusisten in the following countries:
International Drug Name Search
Mejoral Cafeina may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Mejoral Cafeina in the following countries:
Caffeine is reported as an ingredient of Mejoral Cafeina in the following countries:
International Drug Name Search
Vosol is a brand name of acetic acid otic, approved by the FDA in the following formulation(s):
Yes. The following products are equivalent to Vosol:
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vosol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Vosol.
Longcardio may be available in the countries listed below.
Carvedilol is reported as an ingredient of Longcardio in the following countries:
International Drug Name Search
Amocetin may be available in the countries listed below.
Nimesulide is reported as an ingredient of Amocetin in the following countries:
International Drug Name Search
Sultibac may be available in the countries listed below.
Ampicillin sodium salt (a derivative of Ampicillin) is reported as an ingredient of Sultibac in the following countries:
Sulbactam sodium salt (a derivative of Sulbactam) is reported as an ingredient of Sultibac in the following countries:
Sultamicillin is reported as an ingredient of Sultibac in the following countries:
International Drug Name Search
Trankimazin may be available in the countries listed below.
Alprazolam is reported as an ingredient of Trankimazin in the following countries:
International Drug Name Search
Generic Name: doxorubicin liposomal (DOZ oh ROO bi sin LYE poe SOE mal)
Brand Names: Doxil
Doxorubicin liposomal is a cancer (antineoplastic) medication. Doxorubicin liposomal interferes with the growth of cancer cells and slows their growth and spread in the body.
Doxorubicin liposomal is used to treat metastatic ovarian cancer and AIDS-related Kaposi's sarcoma.
Doxorubicin liposomal may also be used for purposes other than those listed in this medication guide.
Doxorubicin liposomal should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.
Serious side effects have been reported with the use of doxorubicin liposomal including: allergic reactions (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives); severe heart damage with prolonged use; decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; fever or chills; or signs of infection); severe nausea, vomiting, diarrhea, and loss of appetite; and others. Talk to your doctor about the possible side effects from treatment with doxorubicin liposomal.
heart disease;
poor bone marrow function;
received radiation therapy that encompassed the heart; or
previously received treatment with doxorubicin (Adriamycin, Rubex), doxorubicin liposomal (Doxil), daunorubicin (Cerubidine), daunorubicin liposomal (Daunoxome), idarubicin (Idamycin), or mitoxantrone (Novantrone).
The use of doxorubicin liposomal may be dangerous if you have any of the conditions listed above.
Doxorubicin liposomal should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.
Your doctor will determine the correct amount and frequency of treatment with doxorubicin liposomal depending upon the type of cancer being treated and other factors. Talk to your doctor if you have any questions or concerns regarding the treatment schedule.
Your doctor will probably want you to have regularly scheduled blood tests and other medical evaluations during treatment with doxorubicin liposomal to monitor progress and side effects.
Skin accidentally exposed to doxorubicin liposomal should be rinsed thoroughly with soap and warm water.
Your healthcare provider will store doxorubicin liposomal as directed by the manufacturer. If you are storing doxorubicin liposomal at home, follow the directions provided by your healthcare provider.
Contact your doctor if you miss a dose of doxorubicin liposomal.
Symptoms of a doxorubicin liposomal overdose tend to be similar to side effects caused by the medication, although often more severe.
Doxorubicin liposomal can lower the activity of your immune system making you susceptible to infections. Avoid contact with people who have colds, the flu, or other contagious illnesses and do not receive vaccines that contain live strains of a virus (e.g., live oral polio vaccine) during treatment with doxorubicin liposomal. In addition, avoid contact with individuals who have recently been vaccinated with a live vaccine. There is a chance that the virus can be passed on to you.
Skin accidentally exposed to doxorubicin liposomal should be rinsed thoroughly with soap and warm water.
If you experience all of the following serious side effects from doxorubicin liposomal, contact your doctor immediately:
an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or signs of infection);
congestive heart failure (difficulty breathing, fluid retention, chest pain);
irregular heartbeats;
tissue or vein reactions near the site of administration;
liver damage (abdominal pain, yellowing of the skin or eyes);
severe nausea, vomiting, diarrhea, and loss of appetite;
inflamation and sores inside the mouth, throat, or intestines;
fever, chills, or other signs of infection;
tingling, burning, redness, flaking, bothersome swelling, small blisters, or small sores on the palms of the hands or soles of the feet;
numbness, tingling, or difficult movement of a body part;
seizures; or
increased levels of uric acid in the body (joint pain and stiffness).
Other, less serious side effects may be more likely to occur. Continue taking doxorubicin liposomal and talk to your doctor if you experience:
facial flushing during administration;
headache;
temporary hair loss; or
red colored urine shortly after receiving a dose (may continue for 1 or 2 days).
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Kaposi's Sarcoma:
20 mg/m2 IV over 30 minutes. The dose should be repeated once every 3 weeks according to patient response.
Usual Adult Dose for Ovarian Cancer:
50 mg/m2 IV at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion-related adverse events are observed, the rate of infusion can be increased to complete administration of the drug over one hour. The patient should be dosed once every four weeks, for as long as the patient does not progress, shows no evidence of cardiotoxicity, and continues to tolerate treatment. A minimum of four courses is recommended because median time to response in clinical trials was four months.
Pretreatment with or concomitant use of antiemetics should be considered.
Usual Adult Dose for Multiple Myeloma:
Initial dose: 30 mg/m2 should be administered as a one hour intravenous infusion on day 4 following bortezomib. With the first doxorubicin liposomal dose, an initial rate of 1 mg/min should be used to minimize the risk of infusion-related reactions.
If no infusion-related adverse reactions are observed, the infusion rate should be increased to complete the administration of the drug over one hour. Patients may be treated for up to 8 cycles until disease progression or the occurrence of unacceptable toxicity.
Drugs other than those listed here may also interact with doxorubicin liposomal. Talk to your doctor and pharmacist before taking any other prescription or over-the-counter medicines, including herbal products, during treatment with doxorubicin liposomal.
See also: doxorubicin liposomal side effects (in more detail)
